Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, ...

NCCN 临床实践指南更新（2025 V1）纳入 MRD 相关重要信息：在 B 细胞淋巴瘤领域，对于一线治疗结束时正电子发射断层扫描（PET）呈阳性的弥漫大 B 细胞淋巴瘤（DLBCL）患者，新增循环肿瘤 DNA（ctDNA）检测用于 MRD ...

This multicentre study comprised 3,209 ethnically diverse patients with advanced non-small cell lung cancer (NSCLC), breast ... When the researchers analysed NCCN indication-matched variants ...

在肺癌的治疗领域，非小细胞肺癌（NSCLC）占据了近 80% 的肺癌病例，其中约 30% 的患者处于局部晚期阶段。按照美国国家综合癌症网络（NCCN）指南，对于不可切除的局部晚期非小细胞肺癌（LA-NSCLC），根治性同步放化疗是标准治疗方案。然而近年来，虽然在放疗 ...

Sugemalimab application seeks approval for unresectable stage 3 NSCLC post-chemoradiotherapy, supported by phase 3 GEMSTONE-301 study data. The study showed a 36% reduction in disease progression risk ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

The initiative’s first set of guidelines focuses on non-small cell lung cancer. The National Comprehensive Cancer Network ...

AUSTIN, Texas, February 10, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor ...